HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NPA Alleges US FDA Bends Time As Well As Rules To Stop NAC’s Use As Dietary Ingredient

Executive Summary

Trade group offers timeline for shift in FDA thinking about the amino acid commonly used in supplements in complaint seeking to block agency from preventing sales of NAC-containing supplements. Complaint also attests that, unlike its current stance, FDA in 1993 acknowledged NAC is lawful for use as a dietary ingredient.

You may also be interested in...

NAC In US Supplements: Enforcement Discretion Continues, Open Sign Posted On Rulemaking Door

Final guidance on NAC use in supplements continue FDA's enforcement discretion as agency also notes potential for rulemaking deeming the ingredient a lawful dietary ingredient. But three to five years for a rulemaking is too long, especially when FDA already knows NAC is safe in supplements, industry says.

NAC Gains Tentative Safety Clearance As US Industry Contests FDA's Attempt To Remove It

FDA answers reach supplement industry sounding like a siren that the agency may take same enforcement step it has with NAC with other ingredients long used in supplements. Answers also might not be enough to convince firms to return NAC-containing supplements to their lineups.

Final Conviction In US FDA's Spiked-Supplement Investigation Of Blackstone Labs

James Boccuzzi was the last person sentenced in connection with FDA's investigation of sports supplement firm Blackstone Labs for selling steroid-containing supplements after it ignored agency's warning to stop.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts